Seres Therapeutics Company Profile (NASDAQ:MCRB)

Analyst Ratings

Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $43.14 (294.36% upside)

Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
Show:
DateFirmActionRatingPrice TargetActions
7/29/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2016HC WainwrightInitiated CoverageBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2016Leerink SwannReiterated RatingBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016GuggenheimInitiated CoverageBuy$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$35.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2015Bank of America Corp.UpgradeNeutral -> Buy$41.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Seres Therapeutics (NASDAQ:MCRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.54)($0.54)($0.54)
Q2 20162($0.62)($0.24)($0.43)
Q3 20162($0.49)($0.20)($0.35)
Q4 20162($0.58)($0.11)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Seres Therapeutics (NASDAQ:MCRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016David N CookEVPSell16,000$29.43$470,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Seres Therapeutics (NASDAQ:MCRB)
DateHeadline
07/29/16 05:15 PMCowen & Company Starts Coverage on Seres Therapeutics, Inc. (MCRB) With A Rating Of “Outperform”
07/29/16 05:15 PMCerecor (CERC) Takes Upward Bounce; Seres Therapeutics (MCRB) Chaotic Plummet On Disappointing CDI Drug Study
07/29/16 03:17 PMGut check: Seres Therapeutics shares plunge after microbiome drug fails in trial -
07/29/16 01:01 PMWhy Seres Therapeutics Inc. Is Being Obliterated Today - Shares plunged in reaction to important study results that missed the mark.
07/29/16 08:07 AMCowen & Company Starts Coverage on Seres Therapeutics, Inc. (MCRB) With A Rating Of "Outperform" - Finance Daily
07/29/16 08:07 AMSeres Therapeutics, Inc. (NASDAQ:MCRB) Trading Up – Insiders ... - Finance Daily
07/29/16 08:07 AMSeres Therapeutics (MCRB) Primary Endpoint Not Achieved in SER-109 Phase 2 ECOSPOR Study - StreetInsider.com
07/29/16 07:30 AMSeres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study Call scheduled for 8:30 am ET today -
07/29/16 07:25 AMSeres Therapeutics stock tanks 78% after 'unexpected' negative midstage trial results -
07/29/16 06:18 AMSeres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection - [at noodls] - - Primary efficacy endpoint was not achieved - - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 29, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics ...
07/29/16 06:02 AM7:02 am Seres Therapeutics announces that its SER-109 Phase 2 ECOSPORT study on multiply recurrent Clostridium difficile infection did not achieve its primary endpoint (shares halted) -
07/26/16 05:25 PMInsiders Selling, Short Interest Growing Seres Therapeutics, Inc. (NASDAQ:MCRB) - Finance Daily
07/24/16 04:42 PMMicrobiomics Just Got Bigger: Implications For Seres Therapeutics? - Seeking Alpha
07/23/16 09:02 AMHow Many Seres Therapeutics Inc (NASDAQ:MCRB)'s Analysts Are Bearish? - Consumer Eagle
07/22/16 05:00 PMMicrobiomics Just Got Bigger: Implications For Seres Therapeutics?
07/21/16 05:20 PMSeres Therapeutics Incorporated (NASDAQ:MCRB) Sellers Increased By 12.69% Their Shorts - Consumer Eagle
07/21/16 07:56 AMTracking Analyst Ratings and Target Projections for: Seres Therapeutics Inc (NASDAQ:MCRB) - Press Telegraph
07/19/16 11:14 AMSolid Performer in Focus: Seres Therapeutics, Inc. (NASDAQ:MCRB) - Engelwood Daily
07/19/16 11:14 AMSeres Therapeutics Inc (NASDAQ:MCRB): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 10:24 AMStock in Positive Territory for the Quarter: Seres Therapeutics, Inc. (NASDAQ:MCRB) - Engelwood Daily
07/18/16 10:24 AMTrading Performance and Target Watch for Seres Therapeutics Inc (NASDAQ:MCRB) - Press Telegraph
07/15/16 09:27 AMCrowd Rating and Earnings Recap for Seres Therapeutics Inc (NASDAQ:MCRB) - Telanagana Press
07/15/16 09:27 AMEye on Stock Volatility for: Seres Therapeutics, Inc. (NASDAQ:MCRB) - Engelwood Daily
07/15/16 09:27 AMSeres Therapeutics Incorporated (NASDAQ:MCRB) Shorted Shares Decreased By 10.42% - Consumer Eagle
07/13/16 08:01 AMT2 Biosystems : Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer
07/12/16 12:11 PMSeres Therapeutics Inc (MCRB) Is Attempting To Overturn 1,500 Years Of Medicine -
07/12/16 06:13 AMSeres Therapeutics and Emulate Announce Collaboration to Support the Development of Novel Microbiome Therapeutics for Inflammatory Bowel Disease and other Serious Conditions - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 12, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, and Emulate, Inc., a private company commercializing the Organs-on-Chips ...
07/11/16 05:08 PMSeres Therapeutics Inc (NASDAQ:MCRB) Is Attempting To Overturn 1,500 Years Of Medicine
07/11/16 09:47 AMSeres Therapeutics Inc (NASDAQ:MCRB) Is Attempting To Overturn 1500 Years Of Medicine - Market Exclusive
07/08/16 05:12 PMWill Seres Therapeutics Inc (NASDAQ:MCRB) Surprise Analysts This Quarter? - Stocks Daily
07/07/16 06:31 AMSeres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-262 for Primary Clostridium difficile Infection - [at noodls] - - First ever clinical study of a synthetic microbiome therapeutic - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced ...
07/04/16 07:13 AMSeres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : July 4, 2016 -
06/30/16 08:01 AMSeres Therapeutics, Inc. (NASDAQ:MCRB) Trading Up – Insiders Selling, Short Interest Growing
06/30/16 05:00 AMComing Soon: Gut Bacteria That Actually Cure Your Disease -
06/29/16 04:59 PMHow Analysts Feel About Seres Therapeutics Inc After Today's Huge Increase? - Engelwood Daily
06/29/16 03:47 PMFlagship Ventures Names Daniel McIntyre Partner - [PR Newswire] - CAMBRIDGE, Mass., June 29, 2016 /PRNewswire/ -- Flagship Ventures today announced the appointment of Daniel McIntyre to the position of Partner, Strategic Communication. In this new role, he is responsible for communication for Flagship's growing organization as well as for its expanding ecosystem of internally generated start-up companies. "As the innovator in the field of scientific entrepreneurship, Flagship has created a rare community of academic collaborators, financing and business partners, portfolio companies, and a unique ecosystem of science innovation," said McIntyre.
06/28/16 05:00 PMShare Update and Earnings Review for Seres Therapeutics Inc (NASDAQ:MCRB) - Press Telegraph
06/28/16 05:00 PMSeres Therapeutics Inc (NASDAQ:MCRB) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 05:00 PMEquity Research and Technical Review on Seres Therapeutics Inc (NASDAQ:MCRB) - Press Telegraph
06/26/16 09:46 AMStock Tracing Lower on the Week Seres Therapeutics, Inc. (NASDAQ:MCRB) - Engelwood Daily
06/22/16 07:49 AMSeres Therapeutics Announces Collaboration with Massachusetts General Hospital to Identify Microbiome Therapeutics for Obesity and Metabolic Syndrome - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 22, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced a collaboration with Massachusetts General ...
06/20/16 12:19 PMSeres Therapeutics Presents New Data at ASM Microbe 2016, including Characterization of SER-262, the Rationally-Designed, Fermented Microbiome Therapeutic Candidate for Primary Clostridium difficile Infection - [at noodls] - - Initiation of a SER-262 Phase 1b study, a first ever for a synthetic microbiome therapeutic, is expected to begin in mid-2016 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2016-- Seres Therapeutics, ...
06/17/16 03:41 PMSERES THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 05:04 PMCowen & Company Initiates Coverage on Seres Therapeutics Inc to Outperform - TheFounders Daily
06/11/16 07:56 AMNestle's Foray Into Medicines Could Add $10B in Revenue
06/11/16 07:56 AMCommit To Purchase Seres Therapeutics At $30, Earn 31.9% Annualized Using Options
06/10/16 08:01 AMCommit To Purchase Seres Therapeutics At $30, Earn 31.9% Annualized Using Options - Nasdaq
06/08/16 05:30 PMSERES THERAPEUTICS INC. (NASDAQ:MCRB) Financial Condition Compared to S&P 500 - CML News
06/06/16 08:49 AMInsiders Out, Institutional Investors In, Time To Buy Seres Therapeutics?
06/06/16 06:18 AMSeres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has initiated a sponsored research ...

Social

About Seres Therapeutics

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MCRB
  • CUSIP:
Key Metrics:
  • Previous Close: $10.94
  • 50 Day Moving Average: $31.41
  • 200 Day Moving Average: $28.23
  • P/E Ratio: N/A
  • P/E Growth: -0.39
  • Market Cap: $432.34M
  • Current Year EPS Consensus Estimate: $-1.78 EPS
  • Next Year EPS Consensus Estimate: $-2.11 EPS
Additional Links:
Seres Therapeutics (NASDAQ:MCRB) Chart for Saturday, July, 30, 2016